Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows

Article excerpt

A Phase III clinical trial led by researchers at the University of Utah found that a novel combination treatment can cut the risk of prostate cancer progression in half for certain patients. The study, headed by Dr. Neeraj Agarwal at Huntsman Cancer Institute, tested whether the approach could prevent the disease from advancing to a more aggressive form. The results suggest the treatment could offer a significant benefit for select prostate cancer patients, though details about which patients qualify and how the combination works remain unclear from the headline and description alone.